Collins Stewart
http://www.collins-stewart.com/index.aspCollins Stewart is an independent investment banking group.
-
Notable Analyst Rating Changes 08/23: (JNPR) (NVDA) (JASO) Upgraded; (STP) (WAG) (PEG) Downgraded
-
Analysts Bullish on Human Genome (HGSI) Shares as Investors Selling
-
Collins Stewart Maintans a 'Buy' on Human Genome Sciences (HGSI); Promising Metrics from First Full Q:
-
Collins Stewart Maintains a 'Buy' on Human Genome Sciences (HGSI); April Benlysta Tracking Survey Suggests Encouraging Early Trends
-
Collins Stewart Maintains a 'Buy' on Human Genome Sciences (HGSI); Mgmt Dinner & Physician Feedback
-
Collins Stewart Maintains a 'Buy' on Human Genome Sciences (HGSI); Color on Additional Payor Coverage for Benlysta
-
Collins Stewart Reiterates a 'Buy' on Human Genome Sciences (HGSI); Benlysta Poised for a Solid Launch
-
Collin Stewart Raises Price Target on Human Genome Sciences (HGSI), FDA Approval of Benlysta
-
Human Genome (HGSI) Slammed After BENLYSTA Fails To Hit Secondary Endpoints and European JOULFERON Application Pulled
-
Notable Analyst Rating Changes 04/01: ANN, FL, OCR, AYI Upgraded; RIMM, BLK, DWA, AIB Downgraded
-
Two Brokerage Firms Step to the Plate - Initiate Human Genome Sciences (HGSI) With a "Buy"
-
Jesup & Lamont Starts Human Genome Sciences (HGSI) at Buy with $35 Price Target
-
Collins Stewart Initiates Coverage on Human Genome Sciences (HGSI) with a Buy

